Crisis in Medical Mycology: The Urgent Need to Adjust Antifungal Breakpoints
Track:
Education Sessions (CE)
Program Code: 269-L01
Date: Tuesday, December 4, 2012
Time: 4:00 PM to 5:00 PM EST
Location:
South Seas D, Level 3, South Convention Center
PRESENTER:
Click the plus sign to see more detailed information about each speaker.
Nathan Wiederhold, PharmD, Associate Professor, University of Texas at Austin
Dr. Nathan P. Wiederhold is Associate Professor at the University of Texas at Austin, College of Pharmacy and Adjoint Associate Professor, at University of Texas Health Science Center in San Antonio. He received his Pharm.D. from the University of Texas at Austin in 2000. He completed pharmacy practice and infectious diseases clinical residencies at Barnes Jewish Hospital, St. Louis, Missouri. He then completed a research fellowship in antifungal pharmacology/medical mycology at the University of Houston and UT MD Anderson Cancer in Houston, Texas. Dr. Wiederholds research area includes antifungal pharmacokinetics-pharmacodynamics and pharmacology. He has over 58 peer-reviewed publications in this area, and his work has been supported by the National Institutes of Health, various professional organizations, and industry.
PROGRAM CHAIR:
Click the plus sign to see more detailed information about each speaker.
Nathan Wiederhold, PharmD, Associate Professor, University of Texas at Austin
Dr. Nathan P. Wiederhold is Associate Professor at the University of Texas at Austin, College of Pharmacy and Adjoint Associate Professor, at University of Texas Health Science Center in San Antonio. He received his Pharm.D. from the University of Texas at Austin in 2000. He completed pharmacy practice and infectious diseases clinical residencies at Barnes Jewish Hospital, St. Louis, Missouri. He then completed a research fellowship in antifungal pharmacology/medical mycology at the University of Houston and UT MD Anderson Cancer in Houston, Texas. Dr. Wiederholds research area includes antifungal pharmacokinetics-pharmacodynamics and pharmacology. He has over 58 peer-reviewed publications in this area, and his work has been supported by the National Institutes of Health, various professional organizations, and industry.
Describe the rationale for the change in antifungal clinical breakpoints.
Determine if the fungal isolate is resistant and explain what treatment options exist.
Given a specific patient case, identify factors that increase a patient's risk of treatment failure.